Abstract:The proviral Integration site of Moloney (PIM) kinase is highly expressed in various diseases, including cancer, making the development of selective inhibitors for this protein important. A series of PIM1 inhibitors, triazolo [4, 3-b] pyridazin-3-yl-quinoline derivatives, have been studied to design new inhibitors. The activity and structural features of these derivatives were investigated to understand their interactions with PIM1 using molecular docking, molecular dynamic simulation, and QSAR techniques. In a study of 30 compounds using the structure-activity technique and the MLR method, a linear model with R2 train = 0.91 and R2 test = 0.96 was obtained. The model utilized descriptors such as RDF080v, RDF105v, RDF135v, Mor03v, and H046 to express the structural characteristics of the inhibitors. To enhance the model, the SVR non-linear method with the RBF function was also used, resulting in an improved model with R2 train = 0.98 and R2 test = 0.98. Furthermore, the molecular docking technique was employed to investigate the interaction of compounds with high (compound 25) and low (compound 13) inhibitory activity. It was observed that the rings with nitrogen atoms interacted with the protein. The molecular binding results indicate that groups such as OMe and rings with Nitrogen can enhance the inhibitory activity of the compounds. Additionally, oxygen and nitrogen atoms contribute to an increased number of hydrogen bonds, thereby increasing the inhibitory activity of the compounds. Additionally, the stability and bonding modes of active and inactive compounds were studied using molecular dynamic simulation. Based on the results, four new inhibitors were designed, demonstrating better inhibition efficiency with the PIM1 kinase compared to the reference compounds. Moreover, the designed compounds underwent evaluation for ADMET, yielding promising results.

Synthesis and structure-activity relationships of N - (3 - (1H-imidazol-2-yl) phenyl) - 3-phenylpropionamide derivatives as a novel class of covalent inhibitors of p97/VCP ATPase

Discovery of Novel Pyrimidine Molecules Containing Boronic Acid As VCP/p97 Inhibitors.

A targeted covalent inhibitor of p97 with proteome-wide selectivity

Developing of Pharmacophore and Three-Dimensional Structure-Activity Relationship Models of VCP/p97 Ligands and Their Synthesis and Biological Evaluation

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on N -Benzylpyrimidin-4-amine Derivatives As VCP/p97 Inhibitors

Discovery of Irreversible P97 Inhibitors

Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors

Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Discovery of Novel Covalent Proteasome Inhibitors Through a Combination of Pharmacophore Screening, Covalent Docking, and Molecular Dynamics Simulations.

Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase

Evaluating P97 Inhibitor Analogues for Their Domain Selectivity and Potency Against the P97–p47 Complex

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Insights into Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism.

Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer

Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.

Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones As Highly Potent and Selective Phosphodiesterase-4 Inhibitors

In silico design and ADMET evaluation of new inhibitors for PIM1 kinase using QSAR studies, molecular docking, and molecular dynamic simulation

Design, Synthesis and Biological Evaluation of Novel 5-Fluoro-1h-benzimidazole-4-carboxamide Derivatives As Potent PARP-1 Inhibitors.